Abstract
Dyslipidemia is said to be present when lipid or lipoprotein levels lie within a range which is known from epidemiological studies to be associated with secondary complications, in particular atherosclerosis of the coronary arteries, or when a lipid or lipoprotein grossly deviates from the norm as in abetalipoproteinemia, hypobetalipoproteinemia or the HDL deficiency syndromes. In most cases, dyslipidemia is due not to a single genetic or environmental factor, but to a combination of the effects of several genes of small effect (polygenes) and environment. In other cases, however, dyslipidemia is caused by a mutation in a single gene of large effect. In such cases, the extent and nature of the phenotype depends primarily on the identity of the gene involved, but is also modulated to an important degree by the nature of the mutation and the genetic and environmental background against which this mutation occurs. In addition, many cases of hyperlipidemia are secondary to other disorders such as hypothyroidism or renal dysfunction. Such disorders may also unmask or exacerbate a genetic lipoprotein disorder. Examples of the latter are the unmasking of type III hyperlipidemia by diabetes mellitus or the exacerbation of familial hype...Continue Reading
References
Jan 1, 1992·Annals of Epidemiology·M Higgins, J B Keller
Jan 1, 1992·Annals of Epidemiology·A D WhiteH A Tyroler
Dec 5, 1992·Lancet·J A HeadyM F Oliver
Dec 14, 1992·The American Journal of Cardiology·G Assmann, H Schulte
Apr 1, 1992·Journal of Clinical Epidemiology·J W FrankR Benfante
Jun 11, 1992·Journal of Clinical Epidemiology·T HarrisA G Schatzkin
Jun 1, 1992·American Journal of Epidemiology·J PekkanenM J Karvonen
Aug 3, 1991·BMJ : British Medical Journal·Z ChenW Li
Dec 19, 1990·JAMA : the Journal of the American Medical Association·J P KaneR J Havel
Mar 1, 1990·American Journal of Epidemiology·L D CowanR B Wallace
Apr 8, 1989·BMJ : British Medical Journal·C G IslesA F Lever
Jun 1, 1989·British Journal of Cancer·N J WaldA Bailey
Oct 25, 1986·Lancet·M J MartinD Wentworth
Feb 9, 1985·British Medical Journal·C E SalmondI A Prior
Mar 8, 1980·Lancet·G Rose, M J Shipley
May 9, 1981·Lancet·S YaariH N Neufeld
May 22, 1981·JAMA : the Journal of the American Medical Association·B PetersonN H Sternby
Jul 1, 1981·American Journal of Epidemiology·A KaganA Nomura
Jul 1, 1981·American Journal of Epidemiology·M R Garcia-PalmieriR J Havlik
Jan 1, 1980·Journal of Chronic Diseases·J D KarkC G Hames
Jan 16, 1981·JAMA : the Journal of the American Medical Association·R R WilliamsT R Dawber
Nov 1, 1995·Journal of the American College of Cardiology·B PittM E McGovern
Oct 29, 1994·Lancet·F M SacksP H Stone
Feb 5, 1994·BMJ : British Medical Journal·M R LawA Bailey
May 1, 1993·American Journal of Epidemiology·A J SchuitF J Kok
Jan 1, 1993·Cardiology·J StamlerR Stamler
Aug 11, 1993·Nucleic Acids Research·S RustG Assmann
Feb 1, 1993·Diabetes Care·J StamlerD Wentworth
Jul 1, 1993·The American Journal of Cardiology·B PittM E McGovern
Jun 1, 1996·The American Journal of Cardiology·G AssmannA von Eckardstein
Citations
Apr 15, 2005·Journal of Human Genetics·Yuko FujitaMitsuru Emi
Jun 11, 2008·Journal of Human Genetics·Yongjun LiuDonna K Arnett
Sep 15, 2004·American Journal of Ophthalmology·Christopher A GirkinRobert N Weinreb
Nov 2, 2001·International Journal of Epidemiology·J LeeK Hughes
Sep 5, 2003·Journal of Human Genetics·Shuji OnoYasushi Saito
Dec 9, 2003·Journal of Human Genetics·Yuko FujitaYasushi Saito
Jan 5, 2008·Journal of Atherosclerosis and Thrombosis·Akiko MiiYasuo Katayama
May 13, 2003·Journal of Atherosclerosis and Thrombosis·Daisuke TakadaMitsuru Emi
Mar 7, 2003·Journal of Atherosclerosis and Thrombosis·Toru YoshimuraKyosuke Yamamoto
Aug 12, 2003·American Journal of Medical Genetics. Part a·Daisuke TakadaMitsuru Emi
Feb 1, 2003·Journal of Atherosclerosis and Thrombosis·Yuki KuromoriKensuke Harada
Sep 9, 2008·Journal of Atherosclerosis and Thrombosis·Manabu WadaTakeo Kato
Jul 17, 1999·Atherosclerosis·O Stein, Y Stein